First Tracks Biotherapeutics Inc cash flow to debt ratio of -1.01K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

First Tracks Biotherapeutics Inc's free cash flow has decreased 13.35% from $-126.16M last year to $-143.01M, signaling decreasing performance

First Tracks Biotherapeutics Inc's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

First Tracks Biotherapeutics Inc's debt has decreased relative to shareholder equity from 0.04 last year to 0.00 today, signaling strengthened financials

First Tracks Biotherapeutics Inc has negative EBITDA, making leverage ratio unreliable

First Tracks Biotherapeutics Inc earns at least as much interest as it pays. Interest obligations are fully covered.

First Tracks Biotherapeutics Inc has insufficient data to evaluate this check.

First Tracks Biotherapeutics Inc's short-term assets of $316.40M exceed its short-term liabilities of $31.02M

First Tracks Biotherapeutics Inc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

First Tracks Biotherapeutics Inc's return on equity of -30.10%, is lower than 15.00%, indicating bad performance

First Tracks Biotherapeutics Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

First Tracks Biotherapeutics Inc had positive net income in only 0.00 out of 5 years, indicating unstable earnings

First Tracks Biotherapeutics Inc has negative free cash flow, indicating the company is burning cash rather than generating it

First Tracks Biotherapeutics Inc has negative free cash flow, indicating cash burn

First Tracks Biotherapeutics Inc's yearly earnings has decreased 1.46% since last year from $-163.71M to $-166.09M, signaling decreasing performance

First Tracks Biotherapeutics Inc's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -40.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

First Tracks Biotherapeutics Inc has insufficient revenue history to calculate 3-year revenue CAGR.

First Tracks Biotherapeutics Inc had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

First Tracks Biotherapeutics Inc had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

First Tracks Biotherapeutics Inc has insufficient data to evaluate this check.

First Tracks Biotherapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

First Tracks Biotherapeutics Inc is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

First Tracks Biotherapeutics Inc has negative or missing EBITDA, making EV/EBITDA ratio unreliable

First Tracks Biotherapeutics Inc has insufficient data to evaluate this check.

First Tracks Biotherapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

First Tracks Biotherapeutics Inc has a price-to-book ratio of 2.16x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

First Tracks Biotherapeutics Inc has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue